Skip to content

Remote Ischemic Preconditioning in Aortic Valve Surgery

Remote Ischemic Preconditioning in Aortic Valve Surgery (RIP-Valve)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01390129
Acronym
RIP-Valve
Enrollment
100
Registered
2011-07-08
Start date
2011-07-31
Completion date
2012-10-31
Last updated
2012-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis

Brief summary

RIP-VALVE is a randomized, single blinded study that will test the hypothesis that remote ischemic preconditioning initiated before surgery reduces post-operative myocardial damage in aortic valve surgery. Infarct size will be determined by 72 hours area under curve of troponin-I.

Detailed description

The hypothesis tested in this research proposal is that remote ischemic preconditioning initiated immediately before aortic valve surgery reduces myocardial damage related to surgery.

Interventions

PROCEDUREControl

Deflated blood pressure cuff placed on upper arm for 30min

PROCEDURERemote ischemic preconditioning

Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 * Aortic valve surgery for aortic stenosis * Written informed consent

Exclusion criteria

* Aortic valve surgery combined with CABG or an other valve surgery * Previous Q-wave myocardial infarction or previous coronary artery bypass graft * Coronary artery stenosis \>70% * Ejection fraction \<35% * Surgery performed in emergency * Nicorandil ou metformin treatment within 8 days before surgery * Patient refusal / patient not having provided written informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Infarct size72 hoursInfarct size as assessed by 72 hours area under curve serum troponin-I

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026